<DOC>
	<DOC>NCT02176668</DOC>
	<brief_summary>The objective of this clinical trial is to explore pharmacodynamics and pharmacokinetics of YH4808 New Formulation in healthy volunteers.</brief_summary>
	<brief_title>The Exploration for Pharmacodynamics and Pharmacokinetics of YH4808 New Formulation in Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>1. healthy adult age 20 to 55 over 55kg with ideal body weight(BMI) 18.5 ~ 25 2. Subject who has no congenital, chronic disease and disease symptoms in medical examination result 3. negative to Helicobacter pylori in 13C urea breath test 4. Subject who judged to be eligible according to various test results including laboratory test(serum test, hematologic/blood chemistry examination, urine test, etc.) and 12lead ECG test performed within 4 weeks before the first IP administration. 5. Subject who agreed to maintain contraception and comply with medically verified contraception methods (including infertility) 1. Subject who has history or presence of clinically significant disease in liver, kidney, nervous system, respiratory system, endocrine system, blood tumor, cardiovascular, reproductive, musculoskeletal system, mental disorder, ophthalmologic disease, and skin disease in investigator's judgement. 2. Subject who has history of surgical operation or disease related to gastrointestinal symptoms (e.g. crohn's diseas, ulcer, etc. except for appendectomy or simple hernia) which could have influence on the absorption of IP. 3. Subject who is hypersensitive to components contained in YH4808 and other drugs(aspirin, antibiotics, etc.) 4. pregnant or lactating woman. 5. Other exclusions apply.</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>